title: Cancer vaccine shows benefit in solid tumors.
abstract: In a phase I clinical trial, the cancer vaccine CDX-1401 was well tolerated in 45 patients with solid tumors and produced some immune responses.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000378:metabolism; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008565:Membrane Proteins